Envista (NVST) vs Pulse Biosciences (PLSE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Pulse Biosciences (PLSE) has outperformed Envista (NVST) over the past year, gaining 150.7% versus a gain of 10.4%. Over five years, PLSE leads with a +130.9% price change compared with -41.3% for NVST. Envista is the larger company by market cap ($3.65 billion vs $3.56 billion), about 1.0 times the size.
Envista converts more of its revenue into profit, with a net margin of 1.7% versus -20794.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NVST | PLSE |
|---|---|---|
| Share price | $22.72 | $49.98 |
| Market cap | $3.65B | $3.56B |
| 1-day change | -1.39% | +1.81% |
| YTD return | +4.65% | +264.02% |
| 1-year return | +10.40% | +150.65% |
| 5-year return | -41.32% | +130.85% |
| P/E ratio (TTM) | 39.17 | — |
| Forward P/E | 13.65 | — |
| EPS (TTM) | $0.58 | $-1.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.72B | $350.00K |
| Revenue growth (YoY) | +8.32% | — |
| Net income (latest FY) | $47.00M | $-72.78M |
| Gross margin | 54.67% | -54.00% |
| Operating margin | 7.95% | -21982.57% |
| Net margin | 1.73% | -20794.57% |
| 52-week high | $30.42 | $58.90 |
| 52-week low | $18.77 | $12.56 |
| Distance from 52-week high | -25.31% | -15.14% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +30.68% | +13.05% |
| Average volume | 2.81M | 506.50K |
| Shares outstanding | 160.62M | 71.32M |
| Employees | 12,000 | 116 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PLSE has outperformed NVST by 140.3 percentage points over the past year.
- Envista is more profitable, keeping 1.7 cents of every revenue dollar as net income versus -20794.6 cents for Pulse Biosciences.
About Envista
NVST stock →Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables.
Health Care · Medical/Dental Instruments · 12,000 employees
About Pulse Biosciences
PLSE stock →Pulse Biosciences, Inc. operates as a novel bioelectric medicine company.
Health Care · Medical/Dental Instruments · 116 employees
NVST vs PLSE FAQ
Which is bigger, Envista or Pulse Biosciences?
Envista (NVST) is larger, with a market capitalization of $3.65B compared with $3.56B for Pulse Biosciences (PLSE).
Which stock has performed better over the past year, NVST or PLSE?
PLSE returned +150.65% over the past 12 months, compared with +10.40% for NVST (price return, excluding dividends). Past performance does not predict future results.
Are Envista and Pulse Biosciences in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.